Forest's Unlikely Co-Sponsor For Ceftaroline Review: FDA Steps In
Executive Summary
FDA got a chance to show off its ability to stimulate antibiotic development during an advisory committee review of a new cephalosporin from Forest Labs. In the past, the agency has been faulted for failing to set clear targets for anti-infective trials; with ceftaroline, the agency went to the other extreme, stepping in to support an application with key re-analyses of data. Reprinted from The RPM Report, November 2010.
You may also be interested in...
Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances
FDA’s effort to create a clearer path for antibiotic development has produced a series of new guidance documents. Those guidances are making some products in development look well-positioned for regulatory review, and rekindling the interest on Wall Street in specialty antibiotic firms.
Forest's Ceftaroline Data Robust Even Under New Antibiotic Efficacy Standards, FDA Says
Sensitivity analyses provide a way around proposed changes in FDA's data requirements for skin infections and community-acquired bacterial pneumonia.
Antibiotic Development Incentive Menu: Options Getting Longer
Congress continues to look at ways to stimulate more research on anti-infectives. The list of potential incentives gets longer each time another drug category wins a new form of incentive. None of the ideas has succeeded yet in coalescing a political consensus; but potential legislative vehicles are out there.